The weight-loss drug market is entering a new phase. After semaglutide and tirzepatide transformed the way obesity is treated, pharmaceutical companies are now competing to develop treatments that can deliver greater weight loss, reduce side effects and give patients more convenient options.
The next generation of obesity medicines is already being tested in clinical trials, with researchers exploring combinations of different hormones, new oral treatments and medicines designed to target several biological pathways at once.
The competition is particularly intense between major pharmaceutical companies such as Eli Lilly and Novo Nordisk, but a growing number of other drugmakers are also developing their own candidates. With the global market for obesity medicines expected to become one of the pharmaceutical industry’s largest markets, companies have strong financial incentives to find the next breakthrough.
Moving Beyond GLP-1
The success of GLP-1 medicines has changed expectations around what pharmaceutical treatment can achieve for people living with obesity.
Semaglutide, the active ingredient in medicines such as Wegovy, helped establish GLP-1 treatment as a major approach to weight management. Tirzepatide then added another mechanism by targeting both GIP and GLP-1 receptors.
Researchers are now asking whether targeting additional biological pathways could produce even greater results.
This is where several next-generation candidates come into the picture. Instead of relying on a single hormone pathway, some experimental medicines are designed to influence two or three pathways simultaneously.
The reasoning is relatively straightforward: obesity involves multiple biological systems that regulate appetite, hunger, glucose metabolism and energy expenditure. Targeting more than one of these systems could potentially produce stronger and more sustained effects.
Retatrutide Has Become One of the Most Closely Watched Candidates
One of the most closely followed experimental medicines is retatrutide, being developed by Eli Lilly.
Unlike semaglutide, which primarily activates the GLP-1 receptor, or tirzepatide, which targets GLP-1 and GIP, retatrutide is designed to activate three receptors: GLP-1, GIP and glucagon.
This triple-action approach has generated significant interest because clinical results have suggested the potential for substantial weight reduction.
In a Phase 3 trial known as TRIUMPH-1, participants receiving the highest 12 mg dose experienced an average 28.3% reduction in body weight after 80 weeks. Lilly reported that 45.3% of participants achieved at least 30% weight loss.
Additional Phase 3 results have also shown meaningful weight reduction among people with obesity and type 2 diabetes, as well as people with obesity and cardiovascular disease. Lilly has said it plans to submit retatrutide to the US Food and Drug Administration in 2027.
Despite the encouraging results, retatrutide peptide remains investigational and is not currently approved for public use. Its safety and effectiveness are still being evaluated through clinical research.
Novo Nordisk Is Taking a Different Approach
Eli Lilly is not the only company working on more advanced obesity treatments.
Novo Nordisk, the company behind Wegovy and Ozempic, is developing several new approaches that go beyond traditional GLP-1 treatment.
One of its most prominent candidates is CagriSema, a combination of semaglutide and cagrilintide. Cagrilintide is an amylin analogue, meaning the treatment is designed to work through a different biological pathway alongside GLP-1 activity.
The company has also been developing zenaglutide, formerly known as amycretin. This experimental medicine combines GLP-1 and amylin activity in a single molecule and is being investigated in both injectable and oral forms.
Recent clinical data suggest that the competition between these newer approaches could become particularly interesting. Novo Nordisk reported in September 2026 that CagriSema produced greater weight loss than a specified dose of tirzepatide in one Phase 3 trial involving people with type 2 diabetes.
The Race Is Also Moving Toward Pills
Injections have become closely associated with modern weight-loss treatment, but pharmaceutical companies are also trying to make effective oral medicines available.
A pill could appeal to people who dislike injections or simply prefer taking a tablet. It could also make treatment easier to integrate into everyday life.
Novo Nordisk is already developing and marketing oral semaglutide options, while Eli Lilly has also advanced oral obesity treatments. Other pharmaceutical companies are developing their own oral GLP-1 candidates.
Recent real-world data have added further interest to the oral market. A study presented in September 2026 found that people switching from injectable weight-loss treatment to Novo Nordisk’s oral Wegovy continued to lose weight during the study period.
However, making a pill that can deliver the same level of effectiveness as injectable treatments remains a major challenge. Researchers must also consider tolerability, dosing, absorption and long-term adherence.
More Weight Loss Is Not the Only Goal
The next generation of obesity treatments is not simply about producing the biggest number on a clinical trial chart.
Researchers like Paradigm Peptides are increasingly looking at other factors that could determine whether a treatment becomes successful.
One important area is tolerability. Gastrointestinal side effects such as nausea, vomiting and diarrhoea can make it difficult for some patients to remain on treatment.
Another issue is body composition. Losing weight does not necessarily mean losing only body fat. Researchers are paying greater attention to preserving lean mass while reducing excess fat.
There is also growing interest in what happens after weight loss. Obesity is a chronic condition, and maintaining lower body weight over the long term remains an important part of treatment.
Some newer medicines are also being investigated for benefits beyond weight itself. Retatrutide, for example, is being studied in conditions including sleep apnoea and knee osteoarthritis associated with obesity.
A Much Bigger Pharmaceutical Race
The competition is no longer limited to Eli Lilly and Novo Nordisk.
According to recent industry reporting, companies including Amgen, Roche, Pfizer, Merck, AstraZeneca, Viking Therapeutics and others are working on different approaches to obesity treatment. These include longer-acting injections, oral medicines, hormone combinations and treatments designed to improve the amount of weight lost while potentially addressing some of the limitations of existing therapies.
This could eventually give doctors more options instead of relying on a small number of blockbuster medicines.
Different patients may respond differently to treatment, meaning the future of obesity medicine may involve selecting therapies based on factors such as effectiveness, side effects, medical history, dosing preferences and other health conditions.
What Comes Next?
The rapid development of new obesity treatments shows how quickly the field is changing.
Semaglutide helped establish the modern weight-loss drug market. Tirzepatide demonstrated the potential of combining hormone pathways. Now, experimental treatments such as retatrutide, CagriSema and newer amylin-based medicines are pushing researchers toward even more sophisticated approaches.
But promising clinical results do not automatically mean a medicine will reach the market. Regulatory approval, long-term safety data, manufacturing capacity, pricing and real-world effectiveness will all influence which treatments ultimately become widely available.
For now, the pharmaceutical industry’s message is clear: the weight-loss drug race is far from over. The next generation of treatments is already being developed, and the coming years could determine whether obesity medicine moves from a small group of blockbuster therapies toward a much broader range of personalised treatment options.
Also Read
